LONDON, June 21 /PRNewswire/ -- Heart failure is a serious morbidity/mortality issue in Europe and presents significant opportunity for cardiac rhythm management (CRM) devices manufacturers. Such growth potential is being reinforced by the increasing number of disease indications considered eligible for implants. As device technologies evolve, manufacturers will need to focus on product innovation and differentiation to leverage emerging market prospects.
Frost & Sullivan (http://www.medicaldevices.frost.com) finds that the European Markets for Cardiac Rhythm Management earned revenues of $1993.8 million in 2005 and estimates this to reach $6298.2 million in 2012.
Hospital admissions for heart failure cases have more than doubled over the past two decades. Moreover, from current estimates of 14 million, cases of heart failure are projected to double by 2020. Such trends are set to augment uptake of CRM devices.
“At the same time, the expansion in the number of disease indications considered eligible for implants and referred for the same will enhance adoption of CRM devices, particularly ICDs and CRT-Ds,” says Frost & Sullivan Industry Analyst Kavitha Ravikumar. “The issue of new guidelines by the European Society of Cardiology (ESC) has designated ICD and cardiac resynchronisation therapy (CRT) devices as class I for patients and have been recognised as a standard of care for many patients with heart failure. “
Encouraged by clinical trials demonstrating the effectiveness of ICDs and CRT-Ds in preventing heart failure, several healthcare institutions have moved to offer reimbursement for their use. While the large body of clinical evidence supporting device implants is expected to cause ICD revenues to grow at an accelerated pace, models showing CRT to be more cost effective than traditional pharmaceutical treatment for heart failure will boost their adoption rates.
However, with most implants in Europe occurring in the public sector hospitals with salaried physicians; the motivation to make a large number of referrals remains limited. Further, as the number of recommended indications for implants increases, physicians - including primary care physicians and general practitioners - will have to be trained to recognise and refer these cases in the early stages itself.
“The average life of a particular design of a CRM device is only two to five years and, therefore, device technologies will need to continually evolve to provide therapeutic improvements over existing treatments,” advises Ms. Ravikumar. “Manufacturers will need to monitor the market and invest in bringing about product innovation and differentiation. Also, as the number of recommended indications for implants increase, physicians will have to be trained to recognise and refer them for suitable CRM implants.”
European Markets for Cardiac Rhythm Management is part of the Medical Devices Subscription, which also includes research in the following markets: European market for Orthopedic Biomaterials and, European Market for Coronary Stents. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Markets for Cardiac Rhythm Management (B672-54) then send an e-mail to Radhika Menon Theodore- Corporate Communications at rmtheodore@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
Contact: Radhika Menon Theodore Corporate Communications - Europe P: +91-44-42044541 F: +91-44-24314264 E: rmtheodore@frost.com Melina Trevino Corporate Communications - Americas P: +1-210-247-2440 F: +1-210-348-1003 E: melina.trevino@frost.com Surbhi Dedhia Corporate Communications - India P: +91-22-5001-3431 E: sdedhia@frost.com Jasminder Kaur Corporate Communications - Asia Pacific P: +65-68900937 E: jkaur@frost.com Sharmin Jassal Corporate Communications - Australia P: +61-2-8247-8900 F: +61-2-9252-8066 E: sjassal@frost.comwww.frost.com
Keywords in this release: Europe, market, cardiac, cardiac rhythm management, CRM, heart failure, CRM devices, cardiac rhythm management device manufacturers, device technologies, implants, ICDs, CRT-Ds, European Society of Cardiology, ESC, cardiac resynchronisation therapy devices, primary care physicians, general medical practitioners
Frost & Sullivan
CONTACT: Contact: Radhika Menon Theodore, Corporate Communications -Europe, P: +91-44-42044541, F: +91-44-24314264, E: rmtheodore@frost.com.Melina Trevino, Corporate Communications - Americas, P: +1-210-247-2440, F:+1-210-348-1003, E: melina.trevino@frost.com. Surbhi Dedhia, CorporateCommunications - India, P: +91-22-5001-3431, E: sdedhia@frost.com.Jasminder Kaur, Corporate Communications - Asia Pacific, P: +65-68900937,E: jkaur@frost.com. Sharmin Jassal, Corporate Communications - Australia,P: +61-2-8247-8900, F: +61-2-9252-8066, E: sjassal@frost.com
